Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

ed and pipeline products; market forces; economic factors such as interest rate and exchange rate fluctuations; the outcome of contingencies such as litigation and investigations; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the regulatory process (including product approvals, labeling and post-marketing actions); scientific developments relating to marketed products or pipeline projects; and media and societal reaction to such developments. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.

* SIMPONI is a trademark owned by Centocor, Inc. and licensed to Schering-Plough for use (subject to regulatory approval) with golimumab products in its territory (including the EU); the SIMPONI trademark is under regulatory review in the U.S.

** The SAPHRIS trademark is under regulatory review in the U.S.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Accuray Incorporated (Nasdaq: ARAY ), a ... that its president and chief executive officer, Euan S. ... Annual J.P. Morgan Healthcare Conference in San Francisco on ... ET. ,, A live webcast of each presentation ... of the Company,s Web site at http://www.accuray.com . ...
(Date:12/16/2009)... A new application developed by American Imaging Management® ... pharmaceuticals has increased health plan staff productivity and ... ,, AIM, a leading diagnostic imaging benefit management ... over 35 million consumers and an operating subsidiary ... adapted the successful clinical and technology platform used ...
(Date:12/16/2009)... REYKJAVIK, Iceland, December 16 Scientists at,deCODE ... journal Nature the,discovery of a version of a ... genome (SNP) with a major impact on susceptibility ... T2D variant is not only large, but unusual:,if ... variant increases risk of,T2D by more than 30% ...
Breaking Medicine Technology:Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4GARP makes the difference 8832 1GARP makes the difference 8832 2Duke Harvard researchers to monitor bonobo reintroduction 8829 1Duke Harvard researchers to monitor bonobo reintroduction 8829 2Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further s 8826 1Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further s 8826 2Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further s 8826 3Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further s 8826 4
... NEW YORK, April 14 The Michael J. Fox,Foundation ... clinical trial,to investigate the potential of inosine -- a ... body -- to slow or stop the progression of,Parkinson,s ... Foundation,s LEAPS (Linked Efforts,to Accelerate Parkinson,s Solutions) 2007 initiative. ...
... Researchers at,the Barbara Ann Karmanos Cancer Institute ... to cancer patients. Today, at the American,Association ... researchers,Vitaly Balan, Ph.D., Pratima Nangia-Makker, Ph.D., and ... rs4644 Foretells Human Breast,Cancer Risk Associated with ...
Other Medicine Technology:Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine 2Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine 3Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 2Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 3
(Date:12/17/2009)... 17 Reportlinker.com announces that a ... its catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ... the animal health industry executives with strategically ... to the development and implementation of effective ... objectives include: ,, To establish ...
(Date:12/17/2009)... following feature is by Devon Herrick, PhD, Senior Fellow ... People often assume they have little control over how ... sickness cannot be scheduled, doctors prescribe treatments and employers ... Americans. However, there are many overlooked ways to trim ... need. ,, Cut your prescription costs: ...
(Date:12/17/2009)... -- The National Council on Disability (NCD) ... Marriott Houston, 5150 Westheimer, Houston, TX, beginning at 8:30 ... 11:00 a.m. on Thursday, January 21, 2010. This meeting ... it is vital to hear from communities around the ... people with disabilities. This meeting will provide another opportunity ...
(Date:12/17/2009)... Maureen Neitz, the husband-and-wife team whose pioneering research may ... vision disorders, as the inaugural recipients of the Jay ... is funded by a $1 million endowment established this ... ,75 and Susan K. Feigenbaum ,74, his wife. The ... , The Neitzes, both of whom are faculty members ...
(Date:12/17/2009)... lung infections , , THURSDAY, Dec. 17 (HealthDay News) -- ... swine flu virus, and researchers say they,ve found a ... severity of the illness appears to be a molecule ... fight off germs and disease. Researchers who analyzed levels ... hospitals last summer found the highest levels in the ...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2
... by the Pharmaceutical Research and Manufacturers of America (PhRMA) ... two of the three leading causes of death of ... are currently in clinical trials or under review by ... disease and stroke are still leading causes of death ...
... announces the launch of Global Health TV, a new ... and civil society on the major health issues faced ... is a collaborative project between HBL Media, a London-based ... Health TV website, http: www.globalhealthtv.com, will bring viewers three ...
... With the advent of a possible new blockbuster drug ... alcohol, and drug addictions, global sales of smoking cessation ... revenues of little over $1.1 billion in 2005 to ... Cessation and Addiction Treatments: A World Market Analysis, a ...
... inventor of Pulse CO-Oximetry and Read-Through Motion and Low ... presented at the Pediatric Academic Societies' (PAS) ... that switching to Masimo SET pulse oximetry technology can ... infants developing retinopathy of prematurity (ROP) by 40%.(1) One ...
... risk factors beyond those expected from weight loss in ... due to the drug itself, reports an article in ... ,Advertisements for rimonabant (sold under the ... 50% of the effects on cardiometabolic risk factors ...
... Medarex, Inc. today announced a collaborative research agreement ... Chemical Holdings Corporation . The two companies expect ... against a Mitsubishi target for the potential treatment ... Medarex's UltiMAb Human Antibody Development System(R) to generate ...
Other Medicine News:Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Masimo SET Pulse Oximetry Technology Significantly Reduce the Risk of ROP 2Health News:Masimo SET Pulse Oximetry Technology Significantly Reduce the Risk of ROP 3Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: